The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

por Chang, Betty Y, Huang, Min Mei, Francesco, Michelle, Chen, Jun, Sokolove, Jeremy, Magadala, Padmaja, Robinson, William H, Buggy, Joseph J
Publicado 2011

Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)

por Owens, Timothy D., Smith, Patrick F., Redfern, Andrew, Xing, Yan, Shu, Jin, Karr, Dane E., Hartmann, Sonja, Francesco, Michelle R., Langrish, Claire L., Nunn, Philip A., Gourlay, Steven G.
Publicado 2021